Generated by All in One SEO v4.8.6, this is an llms.txt file, used by LLMs to index the site.

# Xinnate

Using the body’s natural defense to promote healing

## Sitemaps

- [XML Sitemap](https://xinnate.com/sitemap.xml): Contains all public/indexable URLs for this website.

## Posts

- [debra Care Conference: 26-29 July 2026](https://xinnate.com/debra-care-conference-26-29-july-2026/)
- [Xinnate receives FDA Fast Track Designation for TCP-25 for the Treatment of Epidermolysis Bullosa](https://xinnate.com/xinnate-receives-fda-fast-track-designation-for-tcp-25-for-the-treatment-of-epidermolysis-bullosa/)
- [Xinnate får FDAs Fast Track-status för TCP-25 vid behandling av epidermolysis bullosa](https://xinnate.com/xinnate-far-fdas-fast-track-status-for-tcp-25-vid-behandling-av-epidermolysis-bullosa/)
- [Xinnate Appoints Erik Kinnman as Chairman of the Board](https://xinnate.com/xinnate-appoints-erik-kinnman-as-chairman-of-the-board/)
- [Xinnate utser Erik Kinnman till styrelseordförande](https://xinnate.com/xinnate-utser-erik-kinnman-till-styrelseordforande/)
- [BIO International Convention: 22-25 June 2026](https://xinnate.com/bio-international-convention-22-25-june-2026/)
- [EADV Symposium 2026: 07-09 May 2026](https://xinnate.com/eadv-symposium-2026-07-09-may-2026/)
- [The 3rd World Congress on Rare Skin Diseases: 01-03 July 2026](https://xinnate.com/the-3rd-world-congress-on-rare-skin-diseases-01-03-july-2026/)
- [Xinnate AB har fått patent godkänt i Japan avseende formulering av TCP-25. Patentet är innebär ett ytterligare stärkt globalt immateriellt skydd för TCP-25 gelen.](https://xinnate.com/xinnate-ab-har-fatt-patent-godkant-i-japan-avseende-formulering-av-tcp-25-patentet-ar-innebar-ett-ytterligare-starkt-globalt-immateriellt-skydd-for-tcp-25-gelen/)
- [Xinnate granted patent in Japan for TCP-25 formulation. The patent further strengthens the global intellectual property protection of the TCP-25 gel.](https://xinnate.com/xinnate-granted-patent-in-japan-for-tcp-25-formulation-the-patent-further-strengthens-the-global-intellectual-property-protection-of-the-tcp-25-gel/)
- [Xinnate meddelar att rekryteringen har startat och första patienten har blivit inkluderad i STEP-studien med TCP-25](https://xinnate.com/xinnate-meddelar-att-rekryteringen-har-startat-och-forsta-patienten-har-blivit-inkluderad-i-step-studien-med-tcp-25/)
- [Xinnate announces that recruitment has started and the first patient has been included in the STEP study with TCP-25](https://xinnate.com/xinnate-announces-that-recruitment-has-started-and-the-first-patient-has-been-included-in-the-step-study-with-tcp-25/)
- [Xinnate Completes Oversubscribed Share Issue of SEK 38,5m](https://xinnate.com/xinnate-receives-fda-ind-approval-for-tcp-25-enabling-pivotal-phase-2-3-step-study-in-epidermolysis-bullosa/)
- [Xinnate Receives FDA IND Approval for TCP-25, Enabling Pivotal Phase 2/3 STEP Study in Epidermolysis Bullosa](https://xinnate.com/xinnate-far-fda-godkannande-av-ind-for-tcp-25-och-mojliggor-registreringsgrundande-fas-2-3-studie-for-epidermolysis-bullosa/)
- [First Scientific Publication Reporting Clinical Trial Results for Xinnate’s Proprietary Drug Candidate TCP-25](https://xinnate.com/first-scientific-publication-reporting-clinical-trial-results-for-xinnates-proprietary-drug-candidate-tcp-25/)
- [NLS Days: 13-14 Oct 2025](https://xinnate.com/test-event/)
- [ESDR MEETING: 10-13 Sep 2025](https://xinnate.com/esdr-meeting-10-13-sep-2025/)
- [EB Awareness week: 25-31 Oct 2025](https://xinnate.com/eb-awareness-week-25-31-oct-2025/)
- [Xinnate receives Orphan Drug Designation from US FDA for TCP-25](https://xinnate.com/xinnate-receives-orphan-drug-designation/)
- [EB 2026: 20-22 Jan 2026](https://xinnate.com/eb-2026-international-congress-20-22-jan-2026/)

## Pages

- [1. Home](https://xinnate.com/)
- [Xinnate’s Expanded Access Policy](https://xinnate.com/xinnates-expanded-access-policy/)
- [2. Solution](https://xinnate.com/solution/)
- [STEP study](https://xinnate.com/step-study/)
- [4. R&D](https://xinnate.com/rd/)
- [5. About](https://xinnate.com/about/)
- [7. Contact](https://xinnate.com/contact/)
- [4a. Publications](https://xinnate.com/publications/)
- [All News](https://xinnate.com/all-news/)
- [All Events](https://xinnate.com/all-events/)
- [All Press Releases](https://xinnate.com/all-press-releases/)
- [3. Impact](https://xinnate.com/impact/)
- [6. News and Events](https://xinnate.com/news-and-events/)

## Categories

- [News](https://xinnate.com/category/news/)
- [Events](https://xinnate.com/category/events/)
- [Press Release](https://xinnate.com/category/press-relsease/)

## Tags

- [biotech](https://xinnate.com/tag/biotech/)
- [EB](https://xinnate.com/tag/eb/)
- [biopharma](https://xinnate.com/tag/biopharma/)

## Categories

- [News Page](https://xinnate.com/page_category/news-page/)